Zhou Haoqi, Wang Jingyuan, Asghar Naseem, Liang Baosheng, Song Qianqian, Zhou Xiaohua
Department of Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
Department of Statistics, Abdul Wali Khan University, Mardan 23200, Pakistan.
Diseases. 2023 Dec 1;11(4):176. doi: 10.3390/diseases11040176.
(1) Background: The evidence indicates that comorbidities are associated with an increase in the risk of death from coronavirus disease 2019 (COVID-19). It is unclear whether such an association is different for various combinations of chronic disease comorbidities. (2) Methods: From 16 March 2020 to 30 November 2021, 104,753 patients with confirmed COVID-19 from Khyber Pakhtunkhwa Province, Pakistan, were studied to determine the association between comorbidities and the duration from symptom onset to death in patients with COVID-19 by stratifying their comorbidity status. (3) Results: The patients with comorbidities had an 84% (OR, 0.16; 95% CI, 0.14 to 0.17) decrease in the duration from symptom onset to death, as opposed to patients without a comorbidity. Among the patients with only one comorbidity, chronic lung disease (OR, 0.06; 95% CI, 0.03 to 0.09) had a greater impact on the duration from symptom onset to death than hypertension (OR, 0.15; 95% CI, 0.13 to 0.18) or diabetes (OR, 0.15; 95% CI, 0.12 to 0.18). The patients with both hypertension and diabetes had the shortest duration (OR, 0.17; 95% CI, 0.14 to 0.20) among the patients with two comorbidities. (4) Conclusions: Comorbidity yielded significant adverse impacts on the duration from symptom onset to death in COVID-19 patients in Pakistan. The impact varied with different combinations of chronic disease comorbidities in terms of the number and type of comorbidities.
(1) 背景：有证据表明，合并症与2019冠状病毒病（COVID-19）死亡风险增加相关。尚不清楚这种关联在不同慢性病合并症组合中是否存在差异。(2) 方法：2020年3月16日至2021年11月30日，对巴基斯坦开伯尔-普赫图赫瓦省104753例确诊COVID-19患者进行研究，通过分层合并症状态来确定合并症与COVID-19患者从症状出现到死亡的持续时间之间的关联。(3) 结果：与无合并症患者相比，合并症患者从症状出现到死亡的持续时间减少了84%（比值比，0.16；95%置信区间，0.14至0.17）。在仅有一种合并症的患者中，慢性肺病（比值比，0.06；95%置信区间，0.03至0.09）对从症状出现到死亡的持续时间的影响大于高血压（比值比，0.15；95%置信区间，0.13至0.18）或糖尿病（比值比，0.15；95%置信区间，0.12至0.18）。在有两种合并症的患者中，同时患有高血压和糖尿病的患者持续时间最短（比值比，0.17；95%置信区间，0.14至0.20）。(4) 结论：合并症对巴基斯坦COVID-19患者从症状出现到死亡的持续时间产生了显著不利影响。根据合并症的数量和类型，这种影响在不同慢性病合并症组合中有所不同。
